HC Wainwright Has Pessimistic Outlook of CATX Q3 Earnings

Perspective Therapeutics, Inc. (NYSE:CATX) – Equities researchers at HC Wainwright cut their Q3 2025 earnings per share (EPS) estimates for Perspective Therapeutics in a report issued on Monday, May 19th. HC Wainwright analyst R. Burns now forecasts that the company will post earnings of ($0.31) per share for the quarter, down from their prior forecast of ($0.30). HC Wainwright currently has a “Buy” rating and a $10.00 target price on the stock. The consensus estimate for Perspective Therapeutics’ current full-year earnings is ($0.88) per share. HC Wainwright also issued estimates for Perspective Therapeutics’ FY2025 earnings at ($1.17) EPS, Q2 2026 earnings at ($0.29) EPS, Q3 2026 earnings at ($0.31) EPS and Q4 2026 earnings at ($0.32) EPS.

A number of other analysts have also issued reports on CATX. Truist Financial lowered their price target on Perspective Therapeutics from $10.00 to $8.00 and set a “buy” rating on the stock in a research note on Wednesday, May 14th. Wedbush reaffirmed an “outperform” rating and issued a $11.00 price target on shares of Perspective Therapeutics in a research note on Tuesday, May 13th. Brookline Capital Management raised Perspective Therapeutics to a “strong-buy” rating in a research note on Monday, March 10th. Royal Bank of Canada lowered their price objective on Perspective Therapeutics from $16.00 to $15.00 and set an “outperform” rating on the stock in a research note on Thursday, March 27th. Finally, Scotiabank started coverage on Perspective Therapeutics in a research note on Friday, March 7th. They set a “sector outperform” rating and a $15.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $12.50.

Perspective Therapeutics Stock Down 13.1%

Shares of NYSE:CATX opened at $2.46 on Wednesday. The business’s 50 day moving average price is $2.25 and its 200-day moving average price is $3.51. Perspective Therapeutics has a 1 year low of $1.60 and a 1 year high of $16.70.

Insiders Place Their Bets

In other Perspective Therapeutics news, Director Robert F. Williamson III bought 22,192 shares of Perspective Therapeutics stock in a transaction on Friday, March 28th. The shares were bought at an average price of $2.27 per share, for a total transaction of $50,375.84. Following the completion of the transaction, the director now directly owns 70,837 shares of the company’s stock, valued at $160,799.99. This trade represents a 45.62% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this link. Also, CFO Juan Graham bought 33,333 shares of Perspective Therapeutics stock in a transaction on Friday, March 28th. The stock was acquired at an average price of $2.25 per share, for a total transaction of $74,999.25. Following the transaction, the chief financial officer now directly owns 35,354 shares of the company’s stock, valued at approximately $79,546.50. This trade represents a 1,649.33% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last 90 days, insiders have purchased 115,696 shares of company stock valued at $256,344. Insiders own 3.72% of the company’s stock.

Institutional Investors Weigh In On Perspective Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Deerfield Management Company L.P. Series C raised its position in Perspective Therapeutics by 4.3% in the fourth quarter. Deerfield Management Company L.P. Series C now owns 2,938,754 shares of the company’s stock valued at $9,375,000 after purchasing an additional 120,991 shares during the period. Octagon Capital Advisors LP raised its holdings in shares of Perspective Therapeutics by 62.1% in the 4th quarter. Octagon Capital Advisors LP now owns 2,304,752 shares of the company’s stock valued at $7,352,000 after buying an additional 882,528 shares during the period. Affinity Asset Advisors LLC raised its holdings in shares of Perspective Therapeutics by 71.1% in the 1st quarter. Affinity Asset Advisors LLC now owns 2,224,196 shares of the company’s stock valued at $4,738,000 after buying an additional 924,196 shares during the period. Nicholson Wealth Management Group LLC raised its holdings in shares of Perspective Therapeutics by 0.4% in the 4th quarter. Nicholson Wealth Management Group LLC now owns 1,609,283 shares of the company’s stock valued at $5,134,000 after buying an additional 7,000 shares during the period. Finally, Millennium Management LLC purchased a new stake in shares of Perspective Therapeutics in the 4th quarter valued at $4,132,000. Hedge funds and other institutional investors own 54.66% of the company’s stock.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.